Two-year recurrence-free survival was 100% vs 95.2% among robotic surgery and radiofrequency ablation patients, respectively.
Radical prostatectomy centers that closed from '10 to '14 more likely in areas with strong competition.
A new review shows no significant differences in oncologic outcomes, long-term complications, and health-related quality of life between robot-assisted and open radical cystectomy.
The researchers found lower overall survival among patients undergoing robot-assisted radical cystectomy at hospitals performing 10 or fewer procedures during 2010 to 2012.
Patients with longer hospital stays and pre-discharge complications were at increased risk of readmission within 30 days of discharge.
No benefit of autologous urethral sling placement at robotic assisted radical prostatectomy on early return of continence at 6 months.
In 2013, nearly one third of all minimally invasive radical nephrectomies were performed with robotic assistance.
Predictors of distant recurrences after robot-assisted radical cystectomy were mainly dictated by pathological tumor characteristics.
Robotic partial nephrectomy confers a superior morbidity profile compared to laparoscopic partial nephrectomy.
Robotic surgery may offer some benefits, such as shorter hospital stay and less blood loss.
No significant differences observed in standard oncologic outcomes and quality of life at 12 weeks.
Largest Asian series to date shows a 5-year biochemical recurrence-free survival rate of 76.4%.
Reduced risk of positive surgical margins versus open prostatectomy for patients with pT2 disease only.
Study finds that 85% of all radical prostatectomies performed by urologists in 2013 were robot-assisted procedures, compared with just 22% in 2003.
Advantages in terms of bother and pain surface in a prospective randomized trial comparing suprapubic tubes and urethral catheters.
A retrospective study has shown that the procedure is feasible and was performed safely in selected patients with renal tumors.
Many men are unaware of erectile function recovery time and problems with ejaculation.
Compared with laparoscopic radical prostatectomy, robotic-assisted laparoscopic prostatectomy is associated with a 51% increased likelihood of return of erectile function.
Completely intracorporeal robotic level III inferior vena cava tumor thrombectomy viable.
Nerve-sparing surgery by robot-assisted laparoscopy was associated with a 2.4 times increased odds of regaining potency versus open surgery
Patients are 28% more likely to have partial nephrectomy at hospitals offering robotic-assisted surgery.
In a study, the biochemical recurrence-free and metastasis-free survival rates were 73% and 97.5%, respectively, at 10 years.
Predisposing factors include a history of infection and prior abdominal surgery.
The procedure is safe and can result in good oncologic and function outcomes
A cost analysis of 115 robotic-assisted laparoscopic radical prostatectomies (RARPs) and 358 open radical retropubic prostatectomies (RRPs).
Robotic-assisted laparoscopic radical prostatectomy may have some significant advantages.
An analysis comparing 11,889 men who underwent robot-assisted radical prostatectomy (RARP).
Robotic-assisted radical prostatectomy (RARP) is associated with long-term biochemical relapse-free survival, according to a study presented at the American Urological Association 2012 annual meeting.
WASHINGTON, D.C.—Robot-assisted radical prostatectomy (RARP) for localized prostate cancer (PCa) offers favorable intermediate- and long-term oncologic outcomes, researchers reported at the American Urological Association 2011 annual meeting.
The first long-term study looking at robot-assisted radical prostatectomy has found it is safe and has a low complication rate.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)